Today, Medivir communicated that its Partner Tango Therapeutics has received the approval to start a phase I/II study of TNG348. We update our likelihood of approval for the project.
ANNONS
Today, Medivir communicated that its Partner Tango Therapeutics has received the approval to start a phase I/II study of TNG348. We update our likelihood of approval for the project.